|
|
|
Mutant mice lacking cyclin D1 are entirely resistant to breast tumours induced by neu and ras, genes implicated in most human breast cancers, but are susceptible to those tumours caused by the other oncogenes c-myc and Wnt-1. So Piotr Sicinsky and colleagues of the Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, report in this week’s Nature (Vol. 411, No. 6841, 28 Jun 2001).
Although it remains to be seen whether these findings translate to humans, the results suggest that those human breast cancers caused by neu and ras could be treated with anti-cyclin D1 therapy. Cyclin D1 is one of many proteins involved in cell proliferation. "It might one day be possible to provide tailor-made treatments," say Jiri Bartek and Jiri Lukas of the Institute of Cancer Biology, Danish Cancer Society, Copenhagen, in an accompanying News and Views article. Molecular profiles of breast-cancer patients could be drawn up using DNA chips, or assays. CONTACT: Piotr Sicinsky
tel +1 617 632 5005
e-mail Peter_Sicinski@dfci.harvard.edu Jiri Bartek
tel +45 35 25 73 57
e-mail bartek@biobase.dk
(C) Nature press release.
Message posted by: Trevor M. D'Souza
|
|
Variants Associated with Pediatric Allergic Disorder
Mutations in PHF6 Found in T-Cell Leukemia
Genetic Risk Variant for Urinary Bladder Cancer
Antibody Has Therapeutic Effect on Mice with ALS
Regulating P53 Activity in Cancer Cells
Anti-RNA Therapy Counters Breast Cancer Spread
Mitochondrial DNA Diversity
The Power of RNA Sequencing
‘Pro-Ageing' Therapy for Cancer?
Niche Genetics Influence Leukaemia
Molecular Biology: Clinical Promise for RNA Interference
Chemoprevention Cocktail for Colon Cancer
more news ...
|